[Association of Geriatric Nutritional Risk Index with Adverse Events and Time to Treatment Failure in Malignant Lymphoma Patients Treated with(R-)EPOCH]

Ken Kikuchi; Kaori Yama; Haruna Misaka; Genki Takeda; Taiki Watanabe; Takafumi Souma; Tomoya Harada; Lang Lang; Fumihiko Yamawaki; Tomoyuki Saga; Toshimichi Ishihara; Hideki Sato

[Association of Geriatric Nutritional Risk Index with Adverse Events and Time to Treatment Failure in Malignant Lymphoma Patients Treated with(R-)EPOCH]

Gan To Kagaku Ryoho. 2023 Jun;50(6):701-705.

[Article in Japanese]

Authors

Ken Kikuchi¹, Kaori Yama, Haruna Misaka, Genki Takeda, Taiki Watanabe, Takafumi Souma, Tomoya Harada, Lang Lang, Fumihiko Yamawaki, Tomoyuki Saga, Toshimichi Ishihara, Hideki Sato

Affiliation

¹ Dept. of Pharmacy, Public Interest Association of Medical Service for Workers Kin-Ikyo Chuo Hospital.

PMID: 37317604

Abstract

To date, there are no reports that examine the relationship between geriatric nutritional risk index(GNRI)at the start of chemotherapy for malignant lymphoma and adverse effects. In this study, we investigated the relationship between GNRI at the start of chemotherapy and the incidence of side effects and time to treatment failure(TTF)in(R-)EPOCH-treated patients with relapsed or refractory malignant lymphoma. A significant difference in the incidence of Grade 3 or higher thrombocytopenia was observed between high and low GNRI groups(p=0.043). The GNRI may be an indicator of hematologic toxicity in malignant lymphoma patients treated with(R-)EPOCH. There was a statistically significant difference in TTF between the high and low GNRI groups(p=0.025), suggesting that nutritional status at the start of(R-)EPOCH may affect treatment continuation.

Publication types

English Abstract

MeSH terms

Aged
Humans
Lymphoma* / drug therapy
Nutritional Status
Thrombocytopenia*
Time-to-Treatment
Treatment Failure